Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance-Reference-Cited by-同舟云学术

Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance

Published:2021-10-13 Issue:10 Volume:4 Page:e2128971
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Mathias Joacy G.¹,Nolan Vikki G.²,Klesges Lisa M.³,Badawy Sherif M.⁴,Cooper William O.⁵⁶,Hankins Jane S.⁷,Smeltzer Matthew P.²

Affiliation:

1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill

2. Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, The University of Memphis, Memphis, Tennessee

3. Department of Surgery, Washington University School of Medicine, St Louis, Missouri

4. Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois

5. Department of Pediatrics, Vanderbilt University, Nashville, Tennessee

6. Department of Health Policy, Vanderbilt University, Nashville, Tennessee

7. Department of Hematology, St Jude Children’s Research Hospital, Memphis, Tennessee

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2784920/mathias_2021_ld_210212_1633112292.67145.pdf

Reference6 articles.

1. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study.;Cronin;Hematology,2019

2. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.;Stallworth;Am J Hematol,2010

3. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.;Creary;BMC Res Notes,2015

4. Hydroxyurea for children with sickle cell anemia: Prescribe it early and often.;Ware;Pediatr Blood Cancer,2019

5. Hydroxyurea use for sickle cell disease among Medicaid-enrolled children.;Brousseau;Pediatrics,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High hydroxyurea usage in sickle cell anemia regardless of patient demographics;Pediatric Blood & Cancer;2023-12-09

2. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease;Blood Advances;2023-11-29

3. Descriptive epidemiology of sickle cell disease in Tennessee: population-based estimates from 2008 to 2019;Frontiers in Hematology;2023-11-08

4. Burden of Aging: Health Outcomes Among Adolescents and Young Adults With Sickle Cell Disease;HemaSphere;2023-07-13

5. The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease;Blood Advances;2023-06-30